Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer

Sridhar Mani, John W. Kugler, James A. Knost, David F. Sciortino, Joseph Gibbons, Juan C. Garcia, Rafat H. Ansari, Richard L. Schilsky, Everett E. Vokes

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose rate of 10 mg/m2/min administered weekly for 3 consecutive weeks repeated every 4 weeks revealed a response rate of 4% (90% CI < 1%-18%). There were no complete responses. Treatment with gemcitabine produced moderate to severe toxicity as grade 3-4 neutropenia requiring dose modification was seen in 40% of patients treated. When used in this dose and schedule, gemcitabine does not appear to be effective for patients with metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)275-278
Number of pages4
JournalInvestigational New Drugs
Volume16
Issue number3
DOIs
StatePublished - Dec 1 1998
Externally publishedYes

    Fingerprint

Keywords

  • 150 Minutes
  • Colorectal cancer
  • Gemcitabine
  • Phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Mani, S., Kugler, J. W., Knost, J. A., Sciortino, D. F., Gibbons, J., Garcia, J. C., Ansari, R. H., Schilsky, R. L., & Vokes, E. E. (1998). Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer. Investigational New Drugs, 16(3), 275-278. https://doi.org/10.1023/A:1006100116229